Harvard Bioscience Valuation Multiples

Harvard Bioscience Overview

About Harvard Bioscience

Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, pharmaceutical and therapy discovery, bioproduction, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, and Panlab. The majority of its revenue comes from the United States.

Founded

2000

HQ

Employees

355

Website

harvardbioscience.com

Sectors

Medical DevicesDeepTechHealthTech

Financials (LTM)

Revenue: $87M

EBITDA: $8M

EV

$60M

Valuation Multiples

Multiples.vc

Start free trial

Harvard Bioscience Financials

Harvard Bioscience reported last 12-month revenue of $87M and EBITDA of $8M.

In the same LTM period, Harvard Bioscience generated $51M in gross profit, $8M in EBITDA, and had net loss of ($44M).

Harvard Bioscience P&L

In the most recent fiscal year, Harvard Bioscience reported revenue of $87M and EBITDA of $8M.

Harvard Bioscience expects next 12-month revenue of XXX and NTM EBITDA of XXX

Harvard Bioscience Stock Performance

Harvard Bioscience has current market cap of $24M, and enterprise value of $60M.

Harvard Bioscience's stock price is $5.37.

Harvard Bioscience Valuation Multiples

Harvard Bioscience trades at 0.7x EV/Revenue multiple, and 7.2x EV/EBITDA.

Harvard Bioscience Financial Valuation Multiples

As of April 11, 2026, Harvard Bioscience has market cap of $24M and EV of $60M.

Equity research analysts estimate Harvard Bioscience's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Harvard Bioscience has a P/E ratio of (0.5x).

Harvard Bioscience Margins & Growth Rates

Harvard Bioscience's revenue in the last 12 month grew by 4%.

Harvard Bioscience's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.

Harvard Bioscience's rule of 40 is 13% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Harvard Bioscience's rule of X is 17% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Harvard Bioscience Public Comps

See public comps and valuation multiples for other Medical Devices comps.

Harvard Bioscience M&A Activity

Harvard Bioscience acquired XXX companies to date.

Last acquisition by Harvard Bioscience was on XXXXXXXX, XXXXX. Harvard Bioscience acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Harvard Bioscience Investment Activity

Harvard Bioscience invested in XXX companies to date.

Harvard Bioscience made its latest investment on XXXXXXXX, XXXXX. Harvard Bioscience invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).